Segment and Geographic Information (Tables)

6 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Schedule of financial information for reportable segments

	Three Months Ended March 31,				Six Months Ended March 31,
	2024		2023		2024		2023
Revenue:
Sample Management Solutions	$	74,137	$	71,043	$	153,142	$	146,498
Multiomics		62,218		62,236		124,938		123,325
B Medical Systems		22,779		15,122		35,371		56,944
Total revenue	$	159,134	$	148,401	$	313,451	$	326,767
Adjusted operating loss:
Sample Management Solutions	$	(1,567)	$	(6,076)	$	(2,423)	$	(9,074)
Multiomics		(2,966)		(3,810)		(6,417)		(7,075)
B Medical Systems		(1,153)		(3,367)		(5,562)		2,936
Segment adjusted operating loss		(5,686)		(13,254)		(14,402)		(13,213)
Amortization of completed technology		6,373		4,901		12,000		9,070
Purchase accounting impact on inventory		—		2,912		—		5,781
Amortization of intangible assets other than completed technology		6,654		7,509		13,516		14,882
Transformation costs(1)		4,446		10		4,487		(55)
Restructuring charges		7,344		1,499		8,464		2,961
Impairment of goodwill and intangible assets		115,975		—		115,975		—
Contingent consideration - fair value adjustments		—		(17,145)		—		(17,145)
Merger and acquisition costs and costs related to share repurchase(2)		426		19		4,747		11,857
Other unallocated corporate expenses		51		18		41		98
Total operating loss		(146,955)		(12,977)		(173,632)		(40,662)
Interest income, net		9,565		10,394		19,646		21,059
Other income (expense), net		250		(2,668)		932		(1,523)
Loss before income taxes	$	(137,140)	$	(5,251)	$	(153,054)	$	(21,126)

(1) Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company’s operations, processes and systems to permanently alter the Company’s operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs in the period result from actions taken as part of the Company’s 2024 transformation plan, and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process & systems re-design.

(2) Includes expenses related to governance-related matters.

Schedule of reconciliation of reportable segment assets to corresponding consolidated amounts

Assets:	March 31, 2024		September 30, 2023
Sample Management Solutions	$	845,641	$	675,708
Multiomics		462,684		534,437
B Medical Systems		248,880		511,640
Total assets	$	1,557,205	$	1,721,785

	March 31,		September 30,
	2024		2023
Segment assets	$	1,557,205	$	1,721,785
Cash and cash equivalents, restricted cash and marketable securities		975,358		1,134,256
Deferred tax assets		925		571
Other assets		30,009		29,108
Total assets	$	2,563,497	$	2,885,720

Schedule of revenue from external customers attributed to geographic areas

	Three Months Ended March 31,				Six Months Ended March 31,
	2024		2023		2024		2023
Geographic Location:
United States	$	88,398	$	86,572	$	178,990	$	174,321
Africa		18,942		8,627		26,453		25,837
China		13,646		11,979		28,544		25,387
United Kingdom		5,641		5,789		11,340		11,202
Rest of Europe		23,850		21,432		48,682		60,854
Asia Pacific/Other		8,657		14,002		19,442		29,166
Total revenue	$	159,134	$	148,401	$	313,451	$	326,767